Business
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
Celltrion, Inc. today announced that AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation is now commercially available to patients in the United States.
About this update from Celltrion, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available in the United States ","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"The launch of AVTOZMA SC further diversifies Celltrion's immunology portfolio beyond TNF-alpha and IL-12/23 inhibitors providing a broader range of treatment solutions for immune-mediated inflammatory diseases","length":213,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":410,"olType":false},{"type":"text","content":"INCHEON, South Korea, March 16, 2026 /PRNewswire/ -- Celltrion, Inc. today announced that AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation is now commercially available to patients in the United States.","length":216,"tagName":"p"},{"type":"image","alt":"Celltrion CI (PRNewsfoto/Celltrion)","displaySize":"","headline":null,"caption":"Celltrion CI (PRNewsfoto/Celltrion)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/29f7024eb6887049478f3166bdb174c0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zhv97G9Xy8993_Mur..7KQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/29f7024eb6887049478f3166bdb174c0","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2315627/Celltrion_CI_500px_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"With this launch, Celltrion's AVTOZMA becomes one of the first tocilizumab biosimilars to have both an intravenous (IV) and a SC formulation approved by the U.S. Food and Drug Administration (FDA) and available on the U.S. market.","length":234,"tagName":"p"},{"type":"text","content":""The introduction of AVTOZMA SC is a pivotal moment for Celltrion, underscoring our dedication to delivering effective, accessible and user-friendly therapies for patients with chronic inflammatory diseases," said Thomas Nusbickel, Chief Commercial Officer of Celltrion USA. "By offering both IV and SC formulations, we aim to provide patients and healthcare professionals with greater flexibility in treatment decisions, while continuing to broaden our immunology portfolio with therapies that address...